Pharma News

The development and availability of medicines and vaccines for all patients in the European Union, including those with COVID-19, is the number one priority for the European medicines regulatory network. EMA, together with EU Member States and the European Commission, has published a PDF iconplan outlining principles for how the network will ensure that core public and animal health regulatory activities, such as the authorisation, maintenance and supervision of human and veterinary medicines will continue to be carried out during the ongoing COVID-19 pandemic.

Sun Pharmaceutical Industries Ltd and includes its subsidiaries and/or associate companies) has announced that it has received approval from the Drugs Controller General of India (DCGI) to initiate a clinical trial with Nafamostat Mesilate in Covid-19 patients. Nafamostat is approved in Japan for improvement of acute symptoms of pancreatitis and treatment of Disseminated Intravascular Coagulation (DIC).

Eminence Business Media  organized the Pharma GMP, GCP & Quality Management Webinar on  May 14th-15th, 2020.

Patients with a vascular condition called abdominal aortic aneurysm did not benefit from taking the common antibiotic doxycycline for two years to shrink the aneurysm when compared to those who took a placebo, according to a Vanderbilt University Medical Center (VUMC) study published in the Journal of the American Medical Association (JAMA).

Loss of smell (anosmia) and changes in taste (dysgeusia) were strongly associated with SARS-CoV-2, according to a Canadian study published in CMAJ (Canadian Medical Association Journal).

A potential blood-based biomarker for Alzheimer's and other neurodegenerative diseases seems even more promising thanks to new research from a Massachusetts General Hospital-led study. According to this team's work, neurofilament light chain (NfL) has great potential as a biomarker for early detection of Alzheimer's disease and could be also useful for monitoring treatment response for that condition.

Giving beneficial bacteria to stressed mothers during the equivalent of the third trimester of pregnancy prevents an autism-like disorder in their offspring, according to a new animal study by University of Colorado Boulder researchers.

Caption : Human intestine, engineered in the laboratory of Tracy Grikscheit, MD.

Babies with Hirschsprung's disease are born with an incomplete or absent gut nervous system. Children's Hospital Los Angeles investigator Tracy Grikscheit, MD, runs a laboratory that investigates the therapeutic potential of tissue engineering - the induced growth of healthy tissue using stem cells. In a new study, Dr. Grikscheit successfully grew a fully functional gut nervous system - or ENS - in a pre-clinical model. While not yet available clinically, the finding brings surgeons like Dr. Grikscheit one step closer to helping babies in need.